# US Anti Viral Drugs Market

> US Antiviral Drugs Market Research Report: Size, Share, Trend Analysis By Drug Type (Nucleoside Analogues, Non-Nucleoside Analogues, Protease Inhibitors, Neuraminidase Inhibitors), By Therapeutic Area (HIV, Hepatitis, Influenza, Herpes Simplex Virus), By Route of Administration (Oral, Injectable, Topical) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.76%
- **2024:** $ 12.9 Billion
- **2025:** $ 13.52 Billion
- **2035:** $ 21.52 Billion
- **Key Players:** Gilead Sciences (US), AbbVie (US), Merck & Co (US), GlaxoSmithKline (GB), Bristol-Myers Squibb (US), AstraZeneca (GB), Johnson & Johnson (US), Roche (CH), Novartis (CH)

**Report ID:** MRFR/Pharma/16368-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-anti-viral-drugs-market-17896

---

## Market Summary

## **US Antiviral Drugs Market Overview**

As per MRFR analysis, the US Antiviral Drugs Market Size was estimated at 12.32 (USD Billion) in 2023. The US Antiviral Drugs Market Industry is expected to grow from 12.9 (USD Billion) in 2024 to 21.5 (USD Billion) by 2035. The US Antiviral Drugs Market CAGR (growth rate) is expected to be around 4.753% during the forecast period (2025 - 2035).

### **Key US Antiviral Drugs Market Trends Highlighted**

The US antiviral drugs market is experiencing significant growth, driven by various key market drivers, including the increasing prevalence of viral infections such as influenza, HIV, and hepatitis. The rising awareness and demand for effective treatments have put pressure on pharmaceutical companies to innovate and expand their antiviral drug offerings. The recent trend toward personalized medicine, which encompasses tailored treatments suited to individual patient profiles, is becoming more prominent in the US. This shift is supported by advancements in genetic research and technology, highlighting the importance of targeted therapies in increasing treatment efficacy.

Opportunities to be explored in the US market involve the development of broad-spectrum antivirals designed to combat multiple viral pathogens. With the ongoing threat of emerging viruses and pandemics, there is a need for drugs that can quickly adapt to new challenges. Federal initiatives aim to enhance the research and development of antiviral therapies, offering incentives and funding to foster innovation. In recent times, there has been a notable increase in collaboration between government agencies and pharmaceutical companies to expedite the approval processes and enhance access to antiviral medications, especially in light of the COVID-19 pandemic.

This has led to greater public-private partnerships aimed at addressing urgent health threats, which presents further market opportunities. Additionally, the US market is witnessing a trend toward the integration of digital health solutions and telemedicine within antiviral treatment protocols. Patients are increasingly leveraging technology for consultations, monitoring, and accessing treatments, which enhances adherence to medication regimens and improves health outcomes. With the growing emphasis on preventative measures, public health campaigns focused on vaccination and early detection of viral infections are also gaining traction and support, contributing positively to the overall market landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Antiviral Drugs Market Drivers**

### **Rising Incidence of Viral Infections**

The increasing incidence of viral infections, particularly in the United States, is expected to act as a significant driver for the US Antiviral Drugs Market Industry. According to the Centers for Disease Control and Prevention, there were approximately 1.2 million reported cases of HIV in the US in 2021, with new infections continuing to rise. Additionally, the COVID-19 pandemic has further highlighted the need for effective antiviral therapies, leading to increased spending on antiviral drug R&D by major pharmaceutical companies such as Gilead Sciences and Merck.

These companies have been at the forefront of developing innovative antiviral therapies, responding to the urgent public health need. With the substantial rise in viral infections, the demand for antiviral drugs is projected to grow significantly, fostering a robust market environment.

### **Advancements in Research and Development**

The US Antiviral Drugs Market Industry is being propelled forward by significant advancements in Research and Development. The National Institutes of Health has reported a 10% increase in federal funding for biomedical research in recent years, which includes studies focused on antiviral drug development. Additionally, pharmaceutical companies are investing heavily in novel therapeutic approaches, such as Targeted Antiviral Therapy and Monoclonal Antibodies, to improve treatment outcomes for viral infections.

This influx of innovative treatments is critical in a landscape where existing antiviral therapies are facing challenges like resistance. As new and effective antiviral drugs enter the market, the overall market is expected to expand rapidly.

### **Government Support and Policies**

Government support and favorable policies play a crucial role in driving the US Antiviral Drugs Market Industry. Legislative measures, including the 21st Century Cures Act, have facilitated faster approval processes for novel drug therapies, thereby speeding up the introduction of new antiviral medications to the market. The US Food and Drug Administration has significantly reduced the time required for clinical trials through initiatives promoting expedited pathways for drugs that address unmet medical needs.

Moreover, initiatives aimed at combating infectious diseases have also contributed to increased funding for antiviral drug research, further strengthening the market landscape in the US.

### **Aging Population Susceptible to Viral Diseases**

The aging population in the United States represents a significant driver for the US Antiviral Drugs Market Industry as older adults are generally more susceptible to viral diseases, including influenza and hepatitis. According to the U.S. Census Bureau, the population aged 65 and over is projected to reach 73 million by 2030, accounting for approximately 20% of the total US population.

This demographic shift is likely to lead to higher incidences of viral infections, prompting greater demand for antiviral medications. Pharmaceutical companies are responding to this trend by developing age-specific antiviral treatments, further bolstering the market for antiviral drugs in the US.

## **US Antiviral Drugs Market Segment Insights**

### **Antiviral Drugs Market Drug Type Insights**

The US **Antiviral Drugs Market** segmented by Drug Type includes several critical categories, each playing a vital role in the overall market landscape. Nucleoside Analogues, known for their ability to mimic natural nucleosides, are essential in treating viral infections such as HIV and Hepatitis. Their mechanism helps inhibit viral replication, making them indispensable in antiviral therapies. Non-Nucleoside Analogues, while also significant, operate differently by binding to viral enzymes, thereby offering alternative pathways for treatment, particularly in HIV management.

This diversity in mechanism boosts treatment efficacy and provides options for patients who may not respond to Nucleoside Analogues. Protease Inhibitors stand out within the antiviral landscape due to their strategic action on viral proteins, effectively blocking the maturation of viruses. This class of drugs has been a cornerstone in HIV therapy, ensuring prolonged patient response and reduced viral loads. The ongoing evolution of drug resistance in viral pathogens underlines the importance of this category in developing next-generation therapies.

Additionally, Neuraminidase Inhibitors play a critical role in managing influenza outbreaks by hindering viral release from infected cells, showcasing their value not just in routine management but also in epidemic scenarios.

The growth drivers for the US Antiviral Drugs Market are multifaceted, including an increase in viral disease prevalence, expanding populations at risk, and advances in Research and Development initiatives. The ongoing need for effective antiviral therapies creates ample opportunities for market players to innovate and develop new solutions. However, this segment also faces challenges, including rising drug resistance and the high costs associated with drug development and commercialization.

The overall efficiency and adaptability of each Drug Type within the US Antiviral Drugs Market contribute to its dynamic nature and highlight the importance of continued investment and focus within this critical sector of pharmaceutical care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Antiviral Drugs Market Therapeutic Area Insights**

The US Antiviral Drugs Market, notably within the Therapeutic Area, is experiencing noteworthy developments as it addresses a range of viral infections. This segment includes treatments for HIV, Hepatitis, Influenza, and Herpes Simplex Virus, each playing a crucial role in public health. For HIV, advancements in antiviral therapies lead to improved patient outcomes and management of the disease, significantly impacting quality of life. Hepatitis treatment continues to evolve, with successful curative therapies contributing to a decline in chronic cases.

Influenza remains a persistent seasonal challenge, where antiviral medications help reduce morbidity and mortality rates during outbreaks. The Herpes Simplex Virus segment is also significant, as medications provide essential management options for both symptomatic and asymptomatic individuals. The growing prevalence of viral infections coupled with ongoing Research and Development initiatives underscores the importance of this Therapeutic Area. Enhanced awareness, preventive strategies, and the availability of effective therapies will likely drive market growth, marking the US Antiviral Drugs Market as vital in addressing these public health issues.

### **Antiviral Drugs Market Route of Administration Insights**

The US Antiviral Drugs Market is significantly characterized by its Route of Administration, which plays a pivotal role in determining the efficacy and patient compliance of antiviral treatments. Within this framework, Oral administration is crucial as it offers ease of use and convenience, making it widely accepted among patients. Injectable forms often dominate in situations requiring rapid onset of therapeutic action, especially in acute infections, thereby serving a critical need in both hospital and outpatient settings.

Topical administration, though smaller in proportion, is essential for targeted treatment of localized infections, providing direct application and minimizing systemic side effects. Each of these methods presents unique advantages and influences patient choices, contributing to overall market dynamics. Additionally, growing trends towards patient-centric care and the increasing prevalence of viral diseases foster the relevance of these routes, driving advancements in formulation technologies. The ongoing Research and Development efforts focus on enhancing delivery mechanisms for these administration routes, seeking to improve therapeutic outcomes while addressing challenges such as patient adherence and drug bioavailability.

This aspect of the US Antiviral Drugs Market showcases significant growth opportunities, further influenced by regulatory support aimed at expediting the development of novel antiviral therapies.

### **Antiviral Drugs Market Distribution Channel Insights**

The US Antiviral Drugs Market sees significant activity across its Distribution Channel segment, which is essential for delivering critical medications to patients. Hospital Pharmacy plays a vital role, as they are directly linked to patient care, ensuring that antiviral drugs are readily available for inpatient and outpatient use. Retail Pharmacy has also established a strong presence, providing convenience for patients in accessing antiviral therapies, particularly in managing common viral infections.

The growth of Online Pharmacy has revolutionized accessibility; this channel meets the increasing demand for convenience and privacy, especially for patients who prefer home delivery services. Trends such as the rising prevalence of viral infections and the growing emphasis on rapid diagnostics drive this market. Additionally, regulatory actions and partnerships within the healthcare ecosystem present opportunities for expanding these distribution avenues further. Overall, the US Antiviral Drugs Market segmentation across Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy highlights the diverse strategies employed to ensure medication availability and effective patient engagement.

## **US Antiviral Drugs Market Key Players and Competitive Insights**

The US Antiviral Drugs Market has seen significant growth and intensified competition in recent years, driven by increasing incidences of viral infections, rising investments in research and development, and the urgent need for effective treatment options. This market is characterized by a diverse range of players, including large pharmaceutical corporations and specialized biotech firms, all vying for a competitive edge through innovative drug development, strategic partnerships, and market positioning. Companies are focusing on expanding their product pipelines and enhancing their product offerings to meet the growing demand for antiviral therapies.

The competitive landscape reveals a dynamic environment where companies are leveraging advanced technologies and clinical research to introduce novel antiviral agents targeting various viral diseases, including influenza, HIV, and Hepatitis.

Merck and Co has established a strong footing in the US Antiviral Drugs Market, primarily known for its potent antiviral therapies. With a comprehensive portfolio that includes well-regarded vaccines and treatments, Merck enjoys a robust market presence facilitated by its well-established distribution channels and a focus on high-quality research and development. The company’s commitment to innovation has enabled it to bring forth advanced antiviral options that are highly effective, thereby reinforcing its competitive position.

Furthermore, Merck benefits from a strong brand reputation and has frequently engaged in successful collaborations and partnerships with academic institutions and other biotech firms to enhance its research capabilities and drive forward the development of novel antiviral solutions.

AstraZeneca is another formidable player in the US Antiviral Drugs Market, recognized for its extensive range of antiviral medications targeting various viral pathogens. The company's key products include innovative therapies aimed at treating viral infections, contributing to a significant share of its health care offerings within the US. AstraZeneca's strengths lie in its strong market presence, powered by an emphasis on strategic mergers and acquisitions that have broadened its product portfolio and capabilities. The firm has successfully integrated diverse therapeutic areas through acquisitions, fostering an innovative culture that prioritizes cutting-edge research and development.

AstraZeneca's collaboration with healthcare providers and research entities solidifies its position as a leader in the field and enhances its ability to respond to emerging viral challenges through its advanced pipeline of antiviral medications dedicated to combating infectious diseases in the US.

### **Key Companies in the US Antiviral Drugs Market Include**

## **US Antiviral Drugs Market Industry Developments**

The US Antiviral Drugs Market is currently witnessing significant developments, particularly in response to ongoing health crises and advancing treatments. Merck and Co. continues to enhance its antiviral portfolio with the successful rollout of its molnupiravir for COVID-19, highlighting an increased demand for innovative therapies. AstraZeneca's Evusheld is also gaining attention as a preventive option against COVID-19. Recent months have seen Gilead Sciences receive acclaim for its advanced research in antiviral therapies, including the development of novel treatments targeting viral infections beyond COVID-19.

Furthermore, in July 2023, Bristol Myers Squibb announced its acquisition of a small biotech focused on broad-spectrum antiviral agents, bolstering its position within the market. In addition, a notable partnership in the previous year between Pfizer and a leading research institution resulted in promising new antiviral drug candidates. The valuation of companies within this market has shown robust growth due to increased demand for antiviral therapies, driven by an aging population and rising incidences of viral infections.

Recent reports highlight that the US government continues to invest significantly in antiviral Research and Development initiatives, ensuring a strong pipeline for future drug options.

## **US Antiviral Drugs Market Segmentation Insights**

### **Antiviral Drugs Market Drug Type Outlook**

### **Antiviral Drugs Market Therapeutic Area Outlook**

### **Antiviral Drugs Market Route of Administration Outlook**

### **Antiviral Drugs Market Distribution Channel Outlook**

## Market Drivers

### Expansion of Telehealth Services

The expansion of telehealth services in the US is reshaping the landscape of the anti viral-drugs market. With the increasing adoption of telemedicine, patients are more readily accessing healthcare consultations, which facilitates timely diagnosis and treatment of viral infections. This trend is particularly relevant in the context of antiviral therapies, as patients can receive prescriptions for antiviral medications without the need for in-person visits. The convenience and accessibility of telehealth services are likely to enhance patient adherence to antiviral treatment regimens, thereby driving demand within the anti viral-drugs market. As telehealth continues to evolve, it may play a crucial role in improving health outcomes for individuals affected by viral infections.

### Rising Incidence of Viral Infections

The increasing prevalence of viral infections in the US is a primary driver for the anti viral-drugs market. Reports indicate that viral infections, such as influenza and hepatitis, have seen a notable rise, leading to heightened demand for effective antiviral therapies. The Centers for Disease Control and Prevention (CDC) has documented that viral infections account for a significant portion of hospitalizations, which underscores the urgent need for innovative antiviral solutions. This trend is likely to propel investments in research and development within the anti viral-drugs market, as pharmaceutical companies strive to address the growing health crisis. Furthermore, the economic burden associated with viral diseases, estimated in billions of dollars annually, further incentivizes stakeholders to prioritize antiviral drug development, thereby fostering market growth.

### Growing Awareness of Antiviral Treatments

Public awareness regarding the importance of antiviral treatments is on the rise, which is positively impacting the anti viral-drugs market. Educational campaigns and outreach programs have been instrumental in informing the population about the risks associated with viral infections and the availability of effective antiviral medications. This heightened awareness is reflected in increased patient consultations and prescriptions for antiviral drugs, contributing to market expansion. According to recent surveys, approximately 60% of the population now recognizes the significance of antiviral therapies in managing viral infections. Consequently, healthcare providers are more likely to recommend antiviral treatments, further driving demand within the anti viral-drugs market.

### Increased Government Funding for Research

Government initiatives aimed at combating viral diseases are significantly influencing the anti viral-drugs market. In recent years, federal funding for research and development in the field of virology has increased, with allocations reaching upwards of $1 billion annually. This financial support is directed towards fostering innovation in antiviral drug development, enabling researchers to explore novel therapeutic approaches. The National Institutes of Health (NIH) and other governmental bodies are actively promoting collaborations between academia and industry, which is expected to yield breakthroughs in antiviral therapies. As a result, the anti viral-drugs market is likely to experience accelerated growth, driven by the influx of resources dedicated to addressing viral threats and enhancing public health outcomes.

### Emergence of Resistance to Existing Antivirals

The emergence of resistance to existing antiviral medications poses a significant challenge, thereby driving the need for new antiviral drugs in the market. As viral pathogens evolve, they may develop resistance to commonly used antiviral agents, necessitating the development of novel therapies. This phenomenon has been observed in various viral infections, including HIV and hepatitis C, where treatment regimens have become less effective over time. The anti viral-drugs market is responding to this challenge by investing in research aimed at discovering and developing next-generation antiviral agents. The potential for lucrative returns on investment in this area is substantial, as healthcare providers seek effective solutions to combat resistant viral strains.

## Future Outlook

The [Anti Viral Drugs Market](https://www.marketresearchfuture.com/reports/anti-viral-drugs-market-2454) is projected to grow at a 4.76% CAGR from 2025 to 2035, driven by increasing demand for innovative therapies and rising healthcare expenditures.

**New opportunities:**

- Development of personalized antiviral therapies for chronic infections. Expansion of telehealth services for antiviral consultations. Investment in AI-driven drug discovery platforms for faster development.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments.

## Segment Insights

### By Type: Nucleoside Analogues (Largest) vs. Protease Inhibitors (Fastest-Growing)

In the US anti viral-drugs market, the distribution of share among segment values shows a notable prominence of Nucleoside Analogues, which currently holds the largest market share due to its established efficacy against several viral infections. Following closely are Non-Nucleoside Analogues, which have a significant share as well, while Protease Inhibitors and Neuraminidase Inhibitors, though comparatively smaller, have garnered attention for their specific applications in treating viral diseases. Growth trends indicate a robust expansion for Protease Inhibitors, which are increasingly being recognized for their role in newer therapies. The rising incidence of viral infections and advancements in drug formulation are driving demand within the segment. Additionally, ongoing research and development initiatives aimed at enhancing the effectiveness of these inhibitors contribute to their potential market growth, with emerging evidence supporting their use in combination therapies.

Nucleoside Analogues (Dominant) vs. Protease Inhibitors (Emerging)

Nucleoside Analogues are characterized by their ability to mimic the building blocks of DNA or RNA, facilitating their role in impeding viral replication, making them a preferred choice for many antiviral treatments. This dominance is attributed to their long-standing efficacy and established market presence, backed by substantial clinical research. On the other hand, Protease Inhibitors represent an emerging segment demonstrating significant promise in treating various viral infections. Their mechanism of action involves the inhibition of viral proteases, crucial for viral maturation and replication. As ongoing studies showcase their efficacy in combination with other antiviral agents, the market outlook for Protease Inhibitors is increasingly optimistic, positioning them as vital constituents of future therapeutic regimens.

### By Therapeutic Area: HIV (Largest) vs. Influenza (Fastest-Growing)

The market for antiviral drugs is predominantly driven by the HIV segment, capturing a significant share due to high diagnosis rates and extensive treatment regimens. Following HIV, Hepatitis and Herpes Simplex Virus also contribute to market dynamics but with a comparatively lower market share. Influenza, while traditionally viewed as a seasonal concern, has grown in importance owing to emerging strains and increased vaccination efforts, leading to a more noticeable market presence. Growth trends within the US anti viral-drugs market point towards an upward trajectory for the Influenza segment, driven by innovative drug formulations and heightened awareness of antiviral treatments. Meanwhile, HIV remains a robust segment supported by ongoing research and the development of long-acting injectable therapies. The importance of preventive measures, including pre-exposure prophylaxis (PrEP), further solidifies HIV's position as a leading therapeutic area, while Hepatitis and Herpes Simplex also evolve with novel therapeutic approaches.

HIV (Dominant) vs. Influenza (Emerging)

HIV is the dominant therapeutic area within the US anti viral-drugs market, characterized by advanced therapeutic options and a robust patient support infrastructure. The segment encompasses a range of [treatments](../../../reports/fibromyalgia-treatments-market-1879) that cater to varied patient needs, from sustained viral suppression to the promotion of overall wellness. In contrast, Influenza, while emerging, is gaining traction with new antiviral agents that aim to reduce the duration and severity of illness. The rising incidence of influenza epidemics, coupled with an awareness of pandemic preparedness, contributes to its growth. Both segments face unique challenges, including resistance and evolving viral strains, yet maintain significant roles in addressing public health needs.

### By Route of Administration: Oral (Largest) vs. Injectable (Fastest-Growing)

In the US anti viral-drugs market, the market share distribution among the route of administration segments reveals that Oral administration holds a significant share, making it the largest segment. This preference for Oral antiviral drugs is primarily driven by their ease of use and patient compliance, making them a preferred choice for long-term treatment options. Meanwhile, Injectable antiviral drugs, although currently smaller in market share, are rapidly gaining traction due to their effectiveness in emergency situations and acute infections, positioning them as a fast-growing segment in the market. As healthcare professionals increasingly advocate for effective therapies, growth trends in this segment are expected to reflect a rising demand. The convenience of Oral routes, combined with the emergence of innovative Injectable formulations, is encouraging pharmaceutical companies to invest in research and development. Additionally, the increasing prevalence of viral infections is resulting in heightened awareness and acceptance of both administration routes, ultimately driving market expansion and diversification in treatment options.

Oral (Dominant) vs. Injectable (Emerging)

In the US anti viral-drugs market, Oral administration is considered the dominant route of administration due to its widespread acceptance among patients. This segment benefits from formulations that offer convenience and compliance, which are crucial for chronic antiviral therapies. The ability to deliver medication without the need for needles or professional administration enhances patient adherence to treatment regimens. On the other hand, Injectable routes are becoming an emerging choice, primarily for their rapid action and suitability in acute cases. Injectables often demonstrate faster onset of action, appealing to healthcare providers addressing urgent health concerns. The ongoing advancements in delivery mechanisms for injectables also indicate a potential shift towards these alternatives as both segments continue to evolve.

### By Distribution Channel: Hospital Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing)

In the distribution channel segment of the US anti viral-drugs market, Hospital Pharmacy holds the largest market share, primarily due to its crucial role in providing essential medications directly to patients in clinical settings. This channel is favored for its ability to offer a wide range of antiviral treatments tailored for patient needs, ensuring immediate access to life-saving drugs during critical health situations. Conversely, the Online Pharmacy segment is rapidly gaining traction, with an increasing number of consumers opting for the convenience of home delivery, contributing to its growth in market share. The growth trends in this segment are largely driven by the increase in telemedicine and digital health solutions, which have made it easier for patients to consult specialists and obtain prescriptions online. Moreover, the rising demand for convenience and accessibility of medications has prompted more consumers to choose online options, leading to significant investments in digital platforms by pharmaceutical companies. This shift indicates a transformative landscape where both Hospital and Online Pharmacies are expected to coexist, catering to diverse patient needs and preferences.

Hospital Pharmacy (Dominant) vs. Online Pharmacy (Emerging)

Hospital Pharmacy dominates the distribution channel for antiviral drugs due to its integration within healthcare facilities, providing direct access to professional medical support. This channel ensures that patients receive personalized care and prompt access to medication, creating a robust distribution method. In contrast, Online Pharmacy is an emerging player that has gained popularity among tech-savvy consumers looking for efficiency and ease of access. The convenience of ordering medications from home and rapid delivery has made Online Pharmacies an attractive option. As healthcare continues to digitize, Online Pharmacies are expected to grow, providing a complementary service to traditional channels while expanding the overall reach of antiviral drugs.

## Competitive Benchmarking

The anti viral-drugs market is currently characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on addressing emerging viral threats. Key players such as Gilead Sciences (US), AbbVie (US), and Merck & Co (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Gilead Sciences (US) emphasizes research and development, particularly in the realm of novel antiviral therapies, while AbbVie (US) focuses on expanding its portfolio through strategic acquisitions and collaborations. Merck & Co (US) appears to be leveraging its extensive experience in vaccine development to diversify its antiviral offerings, thereby shaping a competitive environment that is increasingly reliant on innovation and strategic alliances. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure is moderately fragmented, with a mix of established players and emerging biotech firms. This fragmentation allows for a diverse range of products and therapeutic approaches, although the collective influence of major companies like Gilead and Merck creates a competitive dynamic that is both challenging and opportunistic for smaller entities. In October 2025, Gilead Sciences (US) announced a partnership with a leading biotech firm to co-develop a next-generation antiviral treatment targeting resistant viral strains. This collaboration is strategically significant as it not only enhances Gilead's research capabilities but also positions the company to address a critical gap in the market for effective antiviral therapies. The partnership underscores Gilead's commitment to innovation and its proactive approach to emerging viral challenges. In September 2025, AbbVie (US) completed the acquisition of a smaller biotech company specializing in antiviral drug delivery systems. This acquisition is pivotal as it allows AbbVie to integrate advanced delivery technologies into its existing antiviral portfolio, potentially improving patient outcomes and expanding market reach. The move reflects AbbVie's strategy to enhance its competitive edge through technological advancements and product differentiation. In August 2025, Merck & Co (US) launched a new antiviral drug aimed at treating a range of viral infections, supported by a robust clinical trial program. This launch is indicative of Merck's strategy to capitalize on its established reputation in the antiviral space while addressing unmet medical needs. The introduction of this drug is expected to strengthen Merck's market position and drive revenue growth in the coming years. As of November 2025, current trends in the anti viral-drugs market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise to accelerate innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to respond swiftly to emerging viral threats. This shift may redefine market dynamics, emphasizing the importance of agility and adaptability in a rapidly changing environment.

## Recent News & Developments

The US Antiviral Drugs Market is currently witnessing significant developments, particularly in response to ongoing health crises and advancing treatments. Merck and Co. continues to enhance its antiviral portfolio with the successful rollout of its molnupiravir for COVID-19, highlighting an increased demand for innovative therapies. AstraZeneca's Evusheld is also gaining attention as a preventive option against COVID-19. Recent months have seen Gilead Sciences receive acclaim for its advanced research in antiviral therapies, including the development of novel treatments targeting viral infections beyond COVID-19.

Furthermore, in July 2023, Bristol Myers Squibb announced its acquisition of a small biotech focused on broad-spectrum antiviral agents, bolstering its position within the market. In addition, a notable partnership in the previous year between Pfizer and a leading research institution resulted in promising new antiviral drug candidates. The valuation of companies within this market has shown robust growth due to increased demand for antiviral therapies, driven by an aging population and rising incidences of viral infections.

Recent reports highlight that the US government continues to invest significantly in antiviral Research and Development initiatives, ensuring a strong pipeline for future drug options.

## Report Scope

| MARKET SIZE 2024 | 12.9(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 13.52(USD Billion) |
| MARKET SIZE 2035 | 21.52(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.76% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Gilead Sciences (US), AbbVie (US), Merck & Co (US), GlaxoSmithKline (GB), Bristol-Myers Squibb (US), AstraZeneca (GB), Johnson & Johnson (US), Roche (CH), Novartis (CH) |
| Segments Covered | Type, Therapeutic Area, Route of Administration, Distribution Channel |
| Key Market Opportunities | Emerging antiviral therapies targeting resistant viral strains present growth opportunities in the anti viral-drugs market. |
| Key Market Dynamics | Regulatory changes and technological advancements drive innovation in the anti viral-drugs market, enhancing treatment options. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall valuation of the US anti viral-drugs market in 2024?**
A: The overall market valuation was $12.9 Billion in 2024.

**Q: What is the projected market valuation for the US anti viral-drugs market by 2035?**
A: The projected valuation for 2035 is $21.52 Billion.

**Q: What is the expected CAGR for the US anti viral-drugs market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during this period is 4.76%.

**Q: Which therapeutic area had the highest valuation in the US anti viral-drugs market in 2024?**
A: The HIV therapeutic area had the highest valuation at $4.5 Billion in 2024.

**Q: What are the projected valuations for Nucleoside Analogues in the US anti viral-drugs market by 2035?**
A: Nucleoside Analogues are projected to reach $6.45 Billion by 2035.

**Q: Which route of administration is expected to have the highest growth in the US anti viral-drugs market?**
A: The Oral route of administration is expected to grow to $8.73 Billion by 2035.

**Q: What was the valuation of the Retail Pharmacy distribution channel in 2024?**
A: The Retail Pharmacy distribution channel was valued at $5.0 Billion in 2024.

**Q: Which key player is known for its leadership in the US anti viral-drugs market?**
A: Gilead Sciences is recognized as a key player in the US anti viral-drugs market.

**Q: What is the projected valuation for Protease Inhibitors in the US anti viral-drugs market by 2035?**
A: Protease Inhibitors are projected to reach $5.38 Billion by 2035.

**Q: How does the valuation of the Online Pharmacy distribution channel compare from 2024 to 2035?**
A: The Online Pharmacy distribution channel is expected to grow from $3.4 Billion in 2024 to $6.2 Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-anti-viral-drugs-market-17896*